STARLING ONCOLOGY INC
STLNNASDAQ🏆 #2683 by market capEarnings Nov 5 · PostUS Equity
$6.43▼ $0.21 (−3.09%)
Latest quoteTrack STLN
Get earnings, price moves & breaking news on Telegram
24h▼ 3.1%
7d▼ 4.0%
14d▲ 0.1%
30d▲ 1.7%
ytd▲ 81.1%
1y▲ 39.8%
🏦Market Cap
$655M
Small Cap
📈Revenue Growth (YoY)
38.4%
High Growth
📊Gross Margin
15.7%
Thin
💵FCF Margin
2.2%
Thin
⚖️P/S Ratio
1.1x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $6.36 – $6.69
- 52-Week Range
- $4.85 – $7.13
- Volume (shares)
- 15,979
- Avg Volume (shares)
- —
- Shares Outstanding
- 101.9M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $503M
- Last Q Revenue
- $161M
- P/E Ratio
- —
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-0.36
- Dividend Yield
- —
STARLING ONCOLOGY INC
STLNFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout STARLING ONCOLOGY INC
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
11 analysts
Strong Buy3
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.